David C. Underwood

Medicine · Health Sciences

21h-index2.8kcitations56works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(25), Neuroscience of respiration and sleep(9), Phosphodiesterase function and regulation(7), Chronic Obstructive Pulmonary Disease (COPD) Research(6), Nitric Oxide and Endothelin Effects(6)

Publications56 total

Glycerine Analysis
2018
Effect of Floor Soil on Coefficient of Friction in Food Service Operations
Ceramic engineering and science proceedings·2008· 4 cited
In vivo modeling systems for chronic obstructive pulmonary disease
Birkhäuser Basel eBooks·2006
Is Patient Acceptability of Oral Sodium Phosphate as Preparation for Colonoscopy as Good as Is Claimed?
Gastrointestinal Endoscopy·2004· 1 cited
<b>Cytokine Activation and Intestinal Mucosal and Renal Dysfunction Are Reduced in Endovascular AAA Repair Compared to Surgery</b>
Journal of Endovascular Therapy·2003· 2 cited
Cytokine Activation and Intestinal Mucosal and Renal Dysfunction are Reduced in Endovascular AAA Repair Compared to Surgery
Journal of Endovascular Therapy·2003· 18 cited
Nonpeptide Tachykinin Receptor Antagonists. III. SB 235375, a Low Central Nervous System-Penetrant, Potent and Selective Neurokinin-3 Receptor Antagonist, Inhibits Citric Acid-Induced Cough and Airways Hyper-reactivity in Guinea Pigs
Journal of Pharmacology and Experimental Therapeutics·2002· 90 citedOpen Access
Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models
The Journal of Immunology·2001· 200 citedOpen Access
Inhibition of p38 MAP Kinase
2001· 2 cited
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
American Journal of Physiology-Lung Cellular and Molecular Physiology·2000· 297 cited
Inhibition of p38 MAP kinase as a therapeutic strategy
Immunopharmacology·2000· 459 cited
SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence
Journal of Pharmacology and Experimental Therapeutics·2000· 244 cited
New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
Current Opinion in Pulmonary Medicine·2000· 63 cited
The Antitussive Activity of δ-Opioid Receptor Stimulation in Guinea Pigs
Journal of Pharmacology and Experimental Therapeutics·2000· 31 cited
The antitussive activity of delta-opioid receptor stimulation in guinea pigs.
PubMed·2000· 67 cited
DIFFERENCES IN TIME-RELATED CARDIOPULMONARY RESPONSES TO HYPOXIA IN THREE RAT STRAINS
Clinical and Experimental Hypertension·2000· 10 cited
Pulmonary inflammation, fibrosis, and disease
Birkhäuser Basel eBooks·2000
In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4receptor antagonist with anti-inflammatory activity
Prostaglandins Leukotrienes and Essential Fatty Acids·1999· 9 cited
cDNA Sequence and Characterization of the Gene that Encodes Human Myotrophin/V-1 Protein, a Mediator of Cardiac Hypertrophy
Journal of Molecular and Cellular Cardiology·1999· 28 cited
ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic
Pulmonary Pharmacology & Therapeutics·1999· 158 cited
page 1 of 3Next →

Frequent Co-authors

Douglas W.P. Hay(21), Ruth R. Osborn(19), Steven Bochnowicz(13), Theodore J. Torphy(9), Mark A. Luttmann(8), Don E. Griswold(7), Charles J. Kotzer(6), Jerry L. Adams(5), Mary S. Barnette(5), Henry M. Sarau(4), T J Torphy(4), Jane K. Matthews(4), Philip J. Kadowitz(4), Martin A. Wasserman(4), John C. Lee(3), Edward F. Webb(3), James J. Foley(3), Giuseppe Giardina(3), Marie Chabot‐Fletcher(3), Tony Kriseman(3)